UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 49

Sortiert nach

Mild Method for Succinimide Hydrolysis on ADCs: Impact on ADC Potency, Stability, Exposure, and Efficacy

Bioconjugate chemistry, 2014-10, Vol.25 (10), p.1871-1880

2014

Volltextzugriff (PDF)

A general approach to site-specific antibody drug conjugates

Proceedings of the National Academy of Sciences - PNAS, 2014-02, Vol.111 (5), p.1766-1771

2014

Volltextzugriff (PDF)

Protection Against Clostridium difficile Infection With Broadly Neutralizing Antitoxin Monoclonal Antibodies

The Journal of infectious diseases, 2012-09, Vol.206 (5), p.706-713

2012

Volltextzugriff (PDF)

On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach

Journal of pharmacokinetics and pharmacodynamics, 2013-10, Vol.40 (5), p.557-571

2013

Volltextzugriff (PDF)

Potent Antitumor Activity of an Auristatin-Conjugated, Fully Human Monoclonal Antibody to Prostate-Specific Membrane Antigen

Clinical cancer research, 2006-04, Vol.12 (8), p.2591-2596

2006

Volltextzugriff (PDF)

The Homodimer of Prostate-Specific Membrane Antigen Is a Functional Target for Cancer Therapy

Proceedings of the National Academy of Sciences - PNAS, 2003-10, Vol.100 (22), p.12590-12595

2003

Volltextzugriff (PDF)

Preclinical PET imaging with the novel human antibody 89Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues

Journal for immunotherapy of cancer, 2021-01, Vol.9 (1)

2021

Volltextzugriff (PDF)

Coordination compounds in nuclear medicine

Chemical reviews, 1993-05, Vol.93 (3), p.1137-1156

1993

Volltextzugriff (PDF)

Targeting of HER2 Antigen for the Treatment of Disseminated Peritoneal Disease

Clinical cancer research, 2004-12, Vol.10 (23), p.7834-7841

2004

Volltextzugriff (PDF)

Synthesis and Biological Evaluation of Novel Macrocyclic Ligands with Pendent Donor Groups as Potential Yttrium Chelators for Radioimmunotherapy with Improved Complex Formation Kinetics

Journal of medicinal chemistry, 2002-08, Vol.45 (16), p.3458-3464

2002

Volltextzugriff (PDF)

Multiplex Immuno-Liquid Chromatography–Mass Spectrometry–Parallel Reaction Monitoring (LC–MS–PRM) Quantitation of CD8A, CD4, LAG3, PD1, PD-L1, and PD-L2 in Frozen Human Tissues

Journal of proteome research, 2018-11, Vol.17 (11), p.3932-3940

2018

Volltextzugriff (PDF)

Abstract P134: Novel EGFRvIII-selective antibody-drug conjugate REGN3124-PBD is strongly efficacious against orthotopic glioblastoma multiforme patient derived xenografts

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P134-P134

2021

Volltextzugriff (PDF)

A Bispecific METxMET Antibody-Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes

Molecular cancer therapeutics, 2023-03, Vol.22 (3), p.357-370

2023

Volltextzugriff (PDF)

PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers

Molecular cancer therapeutics, 2020-10, Vol.19 (10), p.2068-2078

2020

Volltextzugriff (PDF)

In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen

Molecular cancer therapeutics, 2011-09, Vol.10 (9), p.1728-1739

2011

Volltextzugriff (PDF)

Natural Product Splicing Inhibitors: A New Class of Antibody–Drug Conjugate (ADC) Payloads

Bioconjugate chemistry, 2016-08, Vol.27 (8), p.1880-1888

2016

Volltextzugriff (PDF)

Abstract 1131: CD8 immuno-PET using a fully human mAb can detect increases in tumor-infiltrating T cells by a T cell activating immunotherapy

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.1131-1131

2019

Volltextzugriff (PDF)

Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1

Journal of pharmacokinetics and pharmacodynamics, 2020-10, Vol.47 (5), p.513-526

2020

Volltextzugriff (PDF)

Abstract 2092: Characterizing NIR dye-IL13RA2 antibody conjugates for biodistribution studies in xenograft tumor models by fluorescence molecular tomography (FMT)

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2092-2092

2016

Volltextzugriff (PDF)

A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation

Cancer immunology research, 2020-05, Vol.8 (5), p.596-608

2020

Volltextzugriff (PDF)

Abstract 3033: Immuno-PET detection of LAG-3 expressing intratumoral lymphocytes using the zirconium-89 radiolabeled fully human anti-LAG-3 antibody REGN3767

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3033-3033

2018

Volltextzugriff (PDF)

Immuno-PET using Zirconium-89 (^sup 89^Zr) radiolabeled fully human anti-PD-L1 antibody successfully images PD-L1 positive tumors in preclinical mouse models

The Journal of nuclear medicine (1978), 2017-05, Vol.58, p.618

2017

Volltextzugriff (PDF)

Preclinical PET imaging with the novel human antibody 89 Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues

Journal for immunotherapy of cancer, 2021-01, Vol.9 (1), p.e002025

2021

Volltextzugriff (PDF)

Targeted α particle immunotherapy for myeloid leukemia

Blood, 2002-08, Vol.100 (4), p.1233-1239

2002

Volltextzugriff (PDF)

Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054

Cancer immunology research, 2022-10, Vol.10 (10), p.1190-1209

2022

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(49)

Sprache

Englisch
(49)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mild Method for Succinimide Hydrolysis on ADCs: Impact on ADC Potency, Stability, Exposure, and Efficacy

A general approach to site-specific antibody drug conjugates

Protection Against Clostridium difficile Infection With Broadly Neutralizing Antitoxin Monoclonal Antibodies

On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach

Potent Antitumor Activity of an Auristatin-Conjugated, Fully Human Monoclonal Antibody to Prostate-Specific Membrane Antigen

The Homodimer of Prostate-Specific Membrane Antigen Is a Functional Target for Cancer Therapy

Preclinical PET imaging with the novel human antibody 89Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues

Coordination compounds in nuclear medicine

Targeting of HER2 Antigen for the Treatment of Disseminated Peritoneal Disease

Synthesis and Biological Evaluation of Novel Macrocyclic Ligands with Pendent Donor Groups as Potential Yttrium Chelators for Radioimmunotherapy with Improved Complex Formation Kinetics

Multiplex Immuno-Liquid Chromatography–Mass Spectrometry–Parallel Reaction Monitoring (LC–MS–PRM) Quantitation of CD8A, CD4, LAG3, PD1, PD-L1, and PD-L2 in Frozen Human Tissues

Abstract P134: Novel EGFRvIII-selective antibody-drug conjugate REGN3124-PBD is strongly efficacious against orthotopic glioblastoma multiforme patient derived xenografts

A Bispecific METxMET Antibody-Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes

PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers

In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen

Natural Product Splicing Inhibitors: A New Class of Antibody–Drug Conjugate (ADC) Payloads

Abstract 1131: CD8 immuno-PET using a fully human mAb can detect increases in tumor-infiltrating T cells by a T cell activating immunotherapy

Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1

Abstract 2092: Characterizing NIR dye-IL13RA2 antibody conjugates for biodistribution studies in xenograft tumor models by fluorescence molecular tomography (FMT)

A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation

Abstract 3033: Immuno-PET detection of LAG-3 expressing intratumoral lymphocytes using the zirconium-89 radiolabeled fully human anti-LAG-3 antibody REGN3767

Immuno-PET using Zirconium-89 (^sup 89^Zr) radiolabeled fully human anti-PD-L1 antibody successfully images PD-L1 positive tumors in preclinical mouse models

Preclinical PET imaging with the novel human antibody 89 Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues

Targeted α particle immunotherapy for myeloid leukemia

Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054

Suchergebnisse filtern